Otlertuzumab
Product Specifications
UNSPSC Description
Otlertuzumab (TRU-016) is a humanized anti-CD37 monoclonal antibody that can be used for cancer research[1].
Target Antigen
Others
Type
Inhibitory Antibodies
Related Pathways
Others
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/otlertuzumab.html
Purity
99.00
Solubility
10 mM in DMSO
Smiles
[Otlertuzumab]
References & Citations
[1]Byrd JC, et al. A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia. Blood. 2014 Feb 27;123(9):1302-8.|[2]Baum P R, et al. Evaluation of the effect of TRU-016, an anti-CD37 directed SMIP in combination with other therapeutic drugs in models of non-Hodgkin's lymphoma. Journal of Clinical Oncology, 2009, 27(15_suppl): 8571-8571.|[3]Cerveny C G, et al. In vitro and in vivo anti-B cell lymphoma activities of TRU-016. Journal of Clinical Oncology, 2008, 26(15_suppl): 3074-3074.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P99212/Otlertuzumab-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P99212/Otlertuzumab-SDS-MedChemExpress.pdf
Clinical Information
Phase 2
CAS Number
1372645-37-8